Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review

Table 3 Bevacizumab with chemotherapy as induction therapy before chemo-radiotherapy: Overview of the discussed studies

Ref.	Phase	n	Treatment	Stage	Post-operative complications (n)	pCR
Dipetrillo et al[26], 2012	II	25	Induction FOLFOX + BV followed by BV 5 mg/kg, 5-FU 200 mg/m2 daily, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr.	II-III	Infection (4)	20%
					Delayed healing (3)
					Leak/abscess (2)
					Sterile fluid collection (2)
					Ischemic colonic reservoir (1)
					Fistula (1)
Nogué et al[27], 2011	II	47	Induction XELOX + BV followed by BV 5 mg/kg, CAPE 825 mg/m2bid, RT 50.4 Gy in 28 fr.	II-III	Wound infection (10)	36%
					Intra-abdominal infections (7)
					Anastomotic leak (5)
					Stoma complications (2)
					Other (not specified) (10)
Vivaldi et al[28], 2013	II	15	Induction FOLFOXIRI + BV followed by BV 5 mg/kg, CAPE 825 mg/m2bid or 5-FU 225 mg/m2 daily, RT 50.4 Gy in 28 fr.	II-III	Dehiscence of anastomosis (1)	38%

CT: Chemotherapy; CT-RT: Chemo-radiotherapy; BV: Bevacizumab; RT: Radiotherapy; 5-FU: 5-fluorouracil; CAPE: Capecitabine; fr.: Fractions; FOLFOX: 5-FU and oxaliplatin; XELOX: Capecitabine and oxaliplatin; pCR: Pathological complete response.